Starting August 1, 2024, Quickarrays, Inc. will be providing all products and services in place of Pantomics Inc.
SERVICES
CUSTOM TMA
ROUTINE PATHOLOGY
IHC / IMMUNOFLUORESCENCE
ISH / FISH
CONTRACTED SERVICES
PRIMARY IHC ANTIBODIES
PATHOLOGY FIELD
Hermatopathology
DETECTION SYSTEMS
ANCILLARIES
CONTROL TMA
LUC962
Lung cancer tissue array, set 2, non-overlapping with LUC961, 96 cores, 48 cases from normal, premalignant and cancer tissues with progressive grades and TNM stages in duplicates.
Specification
Data Sheet
TNM Grading
Downloads
Price
Size
Availability
$307
1 slide
In-Stock
A | |
B | |
C | |
D | |
E | |
F | |
G | |
H | |












TNM Classification: Lung carcinoma
T- Primary tumor
TX - Primary tumor cannot be assessed or tumor proven by the presence of malignant cell in sputum or bronchial washing but not visualized by imaging of bronchoscopy;
TO - No evidence of primary tumor;
Tis- Carcinoma in situ;
T1 - Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura without bronchoscopic evidence of invasion more proximal than lobular bronchus;
T2 - Tumor with any of the following features of size or extent; more than 3 cm in greatest dimension; involves main bronchus, 2 cm more proximal to carina; invades visceral pleura; associated with atelectasis or obstructive pneumonitis that extends to the hilar region but not involve the entire lung;
T3 - Tumor of any size that directly invades any of the followings: chest wall (including superior sulcus tumor), diaphragm, mediastinal pleura, parietal pericardium; tumors in the main bronchus less than 3 cm distal to the carina; associated with atelectasis or obstructive pneumonitis of entire lung;
T4 - Tumor of any size that invades any of the following: mediastinum, heart, great vessel, trachea, esophagus, vertebral body, carina, separate tumor nodule(s) in the same,lobe; tumor with malignant pleural effusion.
N - Regional lymph nodes
NX - Regional lymph nodes cannot be assessed;
NO - No regional lymph node metastasis;
N1 - Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension;
N2 - Metastasis in ipsilateral mediastinal and/or subcarinal lymph nodes;
N3 - Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral, scalene, or supraclavicular lymph nodes.
M - Distant metastasis
MX - Distant metastasis cannot be assessed MO - No distant metastasis;
M1 - Distant metastasis, including separate tumor nodule(s) in a different lobe (ipsilateral or contralateral).
Human
48
96
1.5 mm
4um
8
12
Paraffin
Notes:
All tissues were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or Startfrost Adhesive slides. They all have a guaranteed six month shelf-life at 4C from the date of shipment. Additional cores not listed are orientation markers and have no data. There maybe <5% core loss per slide but the core retention rate should be >90%.
Bake at 60C for 30 minutes before use. If antigen retrieving is needed, it is always a good idea to start with a protocol with weak to mild strength. Please check our TNM guide as a reference. For IHC related information on products that provide them, please contact us at info@pantomics.com for the most up-to-date information.
For research use only. Designed for IHC or ISH based protein or RNA tissue profiling in evolution and progression of lung cancers.

ARRAY POSITION | IMAGE | SEX | AGE | ANATOMIC SITE | PATHOLOGY | GRADE | STAGE (TNM) |
|---|---|---|---|---|---|---|---|
A01 | M | 34 | Lung | Normal | |||
A02 | F | 39 | Lung | Normal | |||
A03 | F | 40 | Lung | Normal | |||
A04 | M | 49 | Lung | Lung with chalk deposits | |||
A05 | M | 67 | Lung | Chronic inflammation | |||
A06 | M | 52 | Lung | Chronic inflammation | |||
A07 | F | 50 | Lung | Chronic inflammation | |||
A08 | M | 47 | Lung | Chronic inflammation | |||
A09 | M | 58 | Lung | Granuloma | |||
A10 | M | 54 | Lung | Granuloma | |||
A11 | M | 29 | Lung | Tuberculosis, TB granuloma | |||
A12 | F | 64 | Lung | Tuberculosis, TB granuloma | |||
B01 | M | 34 | Lung | Normal | |||
B02 | F | 39 | Lung | Normal | |||
B03 | F | 40 | Lung | Normal | |||
B04 | M | 49 | Lung | Lung with chalk deposits | |||
B05 | M | 67 | Lung | Chronic inflammation | |||
B06 | M | 52 | Lung | Chronic inflammation | |||
B07 | F | 50 | Lung | Chronic inflammation | |||
B08 | M | 47 | Lung | Chronic inflammation | |||
B09 | M | 58 | Lung | Granuloma | |||
B10 | M | 54 | Lung | Granuloma | |||
B11 | M | 29 | Lung | Tuberculosis, TB granuloma | |||
B12 | F | 64 | Lung | Tuberculosis, TB granuloma | |||
C01 | M | 47 | Lung | Squamous cell carcinoma | I | T3N2M0 | |
C02 | M | 37 | Lung | Squamous cell carcinoma | I | T2N0M0 | |
C03 | M | 71 | Lung | Squamous cell carcinoma | I | T2N0M0 | |
C04 | M | 50 | Lung | Squamous cell carcinoma | I~II | T2N0M0 | |
C05 | F | 65 | Lung | Squamous cell carcinoma | II | T2N0M0 | |
C06 | M | 58 | Lung | Squamous cell carcinoma | II | T2N0M0 | |
C07 | M | 62 | Lung | Squamous cell carcinoma | II | T2N0M0 | |
C08 | M | 42 | Lung | Squamous cell carcinoma | II | T2N0M0 | |
C09 | F | 70 | Lung | Squamous cell carcinoma | III | T3N2M0 | |
C10 | M | 67 | Lung | Squamous cell carcinoma | III | T2N1M0 | |
C11 | M | 64 | Lung | Squamous cell carcinoma | III | T4N0M0 | |
C12 | M | 57 | Lung | Squamous cell carcinoma | III | T2N0M0 | |
D01 | M | 47 | Lung | Squamous cell carcinoma | I | T3N2M0 | |
D02 | M | 37 | Lung | Squamous cell carcinoma | I | T2N0M0 | |
D03 | M | 71 | Lung | Squamous cell carcinoma | I | T2N0M0 | |
D04 | M | 50 | Lung | Squamous cell carcinoma | I~II | T2N0M0 | |
D05 | F | 65 | Lung | Squamous cell carcinoma | II | T2N0M0 | |
D06 | M | 58 | Lung | Squamous cell carcinoma | II | T2N0M0 | |
D07 | M | 62 | Lung | Squamous cell carcinoma | II | T2N0M0 | |
D08 | M | 42 | Lung | Squamous cell carcinoma | II | T2N0M0 | |
D09 | F | 70 | Lung | Squamous cell carcinoma | III | T3N2M0 | |
D10 | M | 67 | Lung | Squamous cell carcinoma | III | T2N1M0 | |
D11 | M | 64 | Lung | Squamous cell carcinoma | III | T4N0M0 | |
D12 | M | 57 | Lung | Squamous cell carcinoma | III | T2N0M0 | |
E01 | M | 62 | Lung | Adenocarcinoma | I | T2N0M0 | |
E02 | M | 64 | Lung | Adenocarcinoma | I | T2N0M0 | |
E03 | M | 62 | Lung | Adenocarcinoma | II | T2N0M0 | |
E04 | M | 44 | Lung | Adenocarcinoma | II | T2N0M0 | |
E05 | F | 50 | Lung | Adenocarcinoma | III | T2N1M0 | |
E06 | F | 49 | Lung | Adenocarcinoma | III | T2N0M0 | |
E07 | M | 45 | Lung | Bronchioloalveolar carcinoma | null | T2N0M0 | |
E08 | F | 58 | Lung | Bronchioloalveolar carcinoma | null | T2N0M0 | |
E09 | M | 52 | Lung | Mucinous adenocarcinoma | null | T2N0M0 | |
E10 | M | 58 | Lung | Adenosquamous carcinoma | null | T2N1M0 | |
E11 | M | 73 | Lung | Adenosquamous carcinoma | null | T2N1M0 | |
E12 | M | 49 | Lung | Adenosquamous carcinoma | null | T3N1M0 | |
F01 | M | 62 | Lung | Adenocarcinoma | I | T2N0M0 | |
F02 | M | 64 | Lung | Adenocarcinoma | I | T2N0M0 | |
F03 | M | 62 | Lung | Adenocarcinoma | II | T2N0M0 | |
F04 | M | 44 | Lung | Adenocarcinoma | II | T2N0M0 | |
F05 | F | 50 | Lung | Adenocarcinoma | III | T2N1M0 | |
F06 | F | 49 | Lung | Adenocarcinoma | III | T2N0M0 | |
F07 | M | 45 | Lung | Bronchioloalveolar carcinoma | T2N0M0 | ||
F08 | F | 58 | Lung | Bronchioloalveolar carcinoma | T2N0M0 | ||
F09 | M | 52 | Lung | Mucinous adenocarcinoma | T2N0M0 | ||
F10 | M | 58 | Lung | Adenosquamous carcinoma | T2N1M0 | ||
F11 | M | 73 | Lung | Adenosquamous carcinoma | T2N1M0 | ||
F12 | M | 49 | Lung | Adenosquamous carcinoma | T3N1M0 | ||
G01 | M | 53 | Lung | Papillary adenocarcinoma | T2N1M0 | ||
G02 | F | 63 | Lung | Papillary adenocarcinoma | T2N1M0 | ||
G03 | F | 53 | Lung | Papillary adenocarcinoma | T2N1M0 | ||
G04 | M | 74 | Lung | Undifferentiated carcinoma | T2N1M0 | ||
G05 | M | 50 | Lung | Undifferentiated carcinoma | T2N0M0 | ||
G06 | M | 28 | Lung | Carcinoid | T3N0M0 | ||
G07 | F | 41 | Lung | Neuroendocrine carcinoma | T2N0M0 | ||
G08 | M | 19 | Lung | Small cell carcinoma | T3N0M0 | ||
G09 | F | 45 | Lung | Small cell carcinoma | T2N0M0 | ||
G10 | M | 45 | Lung | Small cell carcinoma | T2N1M0 | ||
G11 | M | 45 | Lung | Metastatic cancer | |||
G12 | F | 35 | Lung | Metastatic adenocarcinoma | |||
H01 | M | 53 | Lung | Papillary adenocarcinoma | T2N1M0 | ||
H02 | F | 63 | Lung | Papillary adenocarcinoma | T2N1M0 | ||
H03 | F | 53 | Lung | Papillary adenocarcinoma | T2N1M0 | ||
H04 | M | 74 | Lung | Undifferentiated carcinoma | T2N1M0 | ||
H05 | M | 50 | Lung | Undifferentiated carcinoma | T2N0M0 | ||
H06 | M | 28 | Lung | Carcinoid | T3N0M0 | ||
H07 | F | 41 | Lung | Neuroendocrine carcinoma | T2N0M0 | ||
H08 | M | 19 | Lung | Small cell carcinoma | T3N0M0 | ||
H09 | F | 45 | Lung | Small cell carcinoma | T2N0M0 | ||
H10 | M | 45 | Lung | Small cell carcinoma | T2N1M0 | ||
H11 | M | 45 | Lung | Metastatic cancer | |||
H12 | F | 35 | Lung | Metastatic adenocarcinoma | |||
null |